Interim Public Health and Clinical Guidance

Administrative Order No. 2023-0002 entitled “Institutionalization of the Expanded National Practice Guidelines Program” mandates the Department of Health (DOH) to publish interim public health and clinical guidance during public health emergencies (PHE) and for emerging and re-emerging infectious diseases (EREID). Interim guidance documents provide timely and essential information to the public and healthcare professionals during uncertain or rapidly evolving situations. By grounding these guidance documents in evidence, the government can make evidence-informed decisions. These guidance documents are developed through internationally accepted methodologies for rapid guideline development. The term “interim” means that while the recommendations are developed with predominantly international resources, the guidance will evolve when more high-quality evidence becomes available.

The following may be used by healthcare providers, policymakers, and the public for guidance during PHEs and EREIDs:

Name of Interim Public Health and Clinical Guidance	Date Issued
Interim Guidelines on the Diagnosis, Treatment, Management and Reporting of E-cigarette or Vaping Product Use Associated Lung Injury (EVALI) and Related Injury Cases and Deaths	September 11, 2023
Interim Guidelines on the Prevention, Detection, Isolation, Treatment, and Reintegration (PDITR) Strategy and Outbreak Response for Pertussis and Diphtheria	August 1, 2023
Interim Guidance for the Diagnosis and Management of Scabies	April 3, 2023
Guidelines on the Prevention, Detection, Isolation, Treatment and Reintegration (PDITR) Strategy for Hand, Foot and Mouth Disease (HFMD)	November 28, 2022
Additional Interim Guidance on the Management of Monkeypox	June 10, 2022
Interim Technical Guidelines for the Implementation of Monkeypox Surveillance, Screening, Management, and Infection Control	May 24, 2022